BRISTOL MYERS SQUIBB / BAIN CAPITAL

Bristol Myers Squibb and Bain Capital today announced the creation of a new independent biopharmaceutical company (“NewCo”) focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients.